Current concepts in psoriasis and its treatment

Abel, 1986, Drugs in exacerbation of psoriasis, J Am Acad Dermatol, 15, 1007, 10.1016/S0190-9622(86)70265-X Abrams, 1999, CTLA4Ig-mediated blockade of a T-cell costimulation in patients with psoriasis vulgaris, J Clin Invest, 103, 1243, 10.1172/JCI5857 Allison, 2002, Mycophenolate mofetil, a rationally designed immunosuppressive drug, Clin Transplant, 7, 96 Altmeyer, 1994, Antipsoriatic effects of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients, J Am Acad Dermatol, 30, 977, 10.1016/S0190-9622(94)70121-0 Anonymous, 1973, Psoriasis-liver-methotrexate interactions, Arch Dermatol, 108, 36, 10.1001/archderm.108.1.36 Anonymous, 1994, British Photodermatology Group guidelines for PUVA, Br J Dermatol, 130, 246, 10.1111/j.1365-2133.1994.tb02910.x Asadullah, 1999, Interleukin 10 treatment of psoriasis. Clinical results of a phase 2 trial, Arch Dermatol, 135, 187, 10.1001/archderm.135.2.187 Asawanaonda, 2000, 308-nm excimer laser for the treatment of psoriasis: a dose response study, Arch Dermatol, 136, 619, 10.1001/archderm.136.5.619 Austad, 1998, Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis, J Eur Acad Dermatol Venereol, 11, 19, 10.1111/j.1468-3083.1998.tb00948.x Baggott, 1999, Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis, Arch Dermatol, 135, 813, 10.1001/archderm.135.7.813 Bata-Csorgo, 1995, Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture, J Clin Invest, 95, 317, 10.1172/JCI117659 Berth-Jones, 1992, A multicentre, parallel-group comparison of clacipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis, Br J Dermatol, 10.1111/j.1365-2133.1992.tb00126.x Berth-Jones, 2000, Treatment of psoriasis with oral liarozole: a dose-ranging study, Br J Dermatol, 143, 1170, 10.1046/j.1365-2133.2000.03884.x Bhushan, 2002, Anti-E-selectin is ineffective in the treatment of psoriasis: a randomised trial, Br J Dermatol, 146, 824, 10.1046/j.1365-2133.2002.04743.x Binderup, 1998, Effects of novel vitamin D analogue (MC903) on cell proliferation and differentiation in vitro and on calcium metabolism in vivo, Biochem Pharmacol, 37, 889, 10.1016/0006-2952(88)90177-3 Boffa, 1995, Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal, Br J Dermatol, 133, 774, 10.1111/j.1365-2133.1995.tb02754.x Borel, 1976, A new lymphocyte agent, Agents Actions, 6, 468, 10.1007/BF01973261 Brandrup, 1982, Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution, Acta Derm-Venereol, 62, 229 Burden, 1998, Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p, J Invest Dermatol, 110, 958, 10.1046/j.1523-1747.1998.00213.x Capon, 1999, Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1, J Invest Dermatol, 112, 32, 10.1046/j.1523-1747.1999.00471.x Chaudhari, 2001, Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial, Lancet, 357, 1842, 10.1016/S0140-6736(00)04954-0 Clark, 1999, Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis, Br J Dermatol, 141, 279, 10.1046/j.1365-2133.1999.02976.x Collins, 1996, 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach, Br J Dermatol, 135, 248, 10.1111/j.1365-2133.1996.tb01155.x Duffy, 1993, Psoriasis in Australian twins, J Am Acad Dermatol, 29, 428, 10.1016/0190-9622(93)70206-9 du Vivier, 1975, Tachyphylaxis to the action of topically applied corticosteroids, Arch Dermatol, 111, 581, 10.1001/archderm.111.5.581 du Vivier, 1974, Treatment of psoriasis with azathioprine, Br Med J, 1, 49, 10.1136/bmj.1.5897.49 Ellis, 2001, Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes, N Engl J Med, 245, 248, 10.1056/NEJM200107263450403 Enlund, 1999, Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden, Eur J Hum Genet, 7, 783, 10.1038/sj.ejhg.5200365 Epstein, 1975, Effects of 8-methoxypsoralen-induced phototoxic effects of mammalian epidermal macromolecule synthesis in vivo, Photochem Photobiol, 24, 325, 10.1111/j.1751-1097.1975.tb06680.x Eyre, 1990, The Koebner response in psoriasis, 135 Faerber, 2001, Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients, Am J Clin Dermatol, 10.2165/00128071-200102010-00007 Farber, 1990, Epidemiology: natural history and genetics, 209 Farber, 1974, Natural history of psoriasis in 61 twin pairs, Arch Dermatol, 109, 207, 10.1001/archderm.109.2.207 Farkas, 2001, Dithranol upregulates IL-10 receptors on the cultured keratinocyte cell line HaCaT, Inflamm Res, 50, 44, 10.1007/s000110050723 Feldman, 2002, Efficacy of the 308-nm excimer laser for treatment of psoriasis; results of a multicenter study, J Am Acad Dermatol, 46, 900, 10.1067/mjd.2002.120454 Finlay, 1997, Quality of life measurement in dermatology: a practical guide, Br J Dermatol, 136, 305, 10.1111/j.1365-2133.1997.tb14934.x Finlay, 1990, Validation of sickness impact profile and psoriasis disability index in psoriasis, Br J Dermatol, 123, 751, 10.1111/j.1365-2133.1990.tb04192.x Fredriksson, 1978, Severe psoriasis—oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 Friedrich, 2002, Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis, J Invest Dermatol, 118, 672, 10.1046/j.1523-1747.2002.01731.x Geilen, 2001, Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients, Br J Dermatol, 144, 583, 10.1046/j.1365-2133.2001.04088.x Ghoreschi, 2001, Interleukin-4 induced immune deviation as therapy for psoriasis, J Invest Dermatol, 117, 465 Gianotti, 1997, Treatment of psoriasis with calcipotriol: time of onset and healing of relapses, Eur J Dermatol, 7, 275 Glickman, 1986, Lepra, psora, psoriasis, J Am Acad Dermatol, 14, 863, 10.1016/S0190-9622(86)70101-1 Goeckerman, 1931, Treatment of psoriasis, Arch Dermatol & Syphilology, 24, 446, 10.1001/archderm.1931.01450010455012 Gollnick, 1996, Oral retinoids—efficacy and toxicity in psoriasis, Br J Dermatol, 135, 6, 10.1111/j.1365-2133.1996.tb15661.x Gordon, 1999, A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis, J Am Acad Dermatol, 41, 728, 10.1016/S0190-9622(99)70008-3 Gottlieb, 2001, Psoriasis, immunopathology and immunomodulation, Dermatol Clin, 19, 649, 10.1016/S0733-8635(05)70306-5 Gottlieb, 1995, Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis, Nat Med, 1, 442, 10.1038/nm0595-442 Gottlieb, 1996, Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes, J Cutan Pathol, 23, 404, 10.1111/j.1600-0560.1996.tb01430.x Gottlieb, 2000, Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multi-center, multiple-dose, placebo-controlled study, J Am Acad Dermatol, 43, 595, 10.1067/mjd.2000.107945 Gottlieb, 2001, Results of a single-dose, dose-escalating trial of an antibody (IDEC-114) in patients with psoriasis, J Invest Dermatol, 117, 840 Gottlieb, 2002, Psoriasis as a model for T cell mediated disease. Immunobiological and clinical effects of treatment with multiple doses of Efalizumab, an anti-CD11a antibody, Arch Dermatol, 138, 591, 10.1001/archderm.138.5.591 Griffiths, 2000, A systematic review of treatments for severe psoriasis, Health Technol Assess, 4, 1, 10.3310/hta4400 Gruss, 1998, Kinetics of photosensitivity in bath-PUVA photochemotherapy, J Am Acad Dermatol, 89, 443, 10.1016/S0190-9622(98)70322-6 Gupta, 1990, Sulphasalazine improves psoriasis: a double-blind analysis, Arch Dermatol, 126, 487, 10.1001/archderm.126.4.487 Henseler, 1985, Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris, J Am Acad Dermatol, 13, 450, 10.1016/S0190-9622(85)70188-0 Heydendael, 2001, Randomised clinical trial of the efficacy and safety of methotrexate and cyclosporin A Horn, 1992, The effects of rapamycin on keratinocytes, J Invest Dermatol, 98, 650 Hughes, 1983, Crohn's disease and psoriasis, N Engl J Med, 308, 101, 10.1056/NEJM198301133080213 Kang, 1998, Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions, Br J Dermatol, 138, 77, 10.1046/j.1365-2133.1998.02029.x Katz, 1999, Acitretin in psoriasis: an overview of adverse effects, J Am Acad Dermatol, 41, S7, 10.1016/S0190-9622(99)70359-2 Kino, 1987, FK506, a novel immunosuppressant isolated from Streptomyces: I. Fermentation, isolation and physico-chemical and biological characteristics, J Antibiot, 40, 1249, 10.7164/antibiotics.40.1249 Kolbach, 1992, Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment, J Am Acad Dermatol, 27, 769, 10.1016/S0190-9622(08)80228-9 Koo, 1999, Systemic sequential therapy for psoriasis: a new paradigm for improved therapeutic results, J Am Acad Dermatol, 41, S25, 10.1016/S0190-9622(99)70363-4 Kragballe, 1990, Calcipotriol (MC 903), a novel vitamin D3 analogue, stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes, Dermatol Res, 282, 164, 10.1007/BF00372616 Kragballe, 1991, Calcipotriol, a novel principle in the treatment of psoriasis vulgaris: results of a double-blind, multicenter, right-left comparison with betamethasone 17-valerate, Lancet, 1, 193, 10.1016/0140-6736(91)92157-W Kragballe, 1998, Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy, Br J Dermatol, 139, 649, 10.1046/j.1365-2133.1998.02461.x Krueger, 2000, Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis, J Am Acad Dermatol, 43, 448, 10.1067/mjd.2000.106515 Krueger, 2001, The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation Patient-Membership survey, Arch Dermatol, 137, 280 Krutmann, 1998, Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy, J Photochem Photobiol B Biol, 44, 159, 10.1016/S1011-1344(98)00139-0 Langner, 1993, Topical calcitriol in the treatment of chronic plaque psoriasis: a double blind study, Br J Dermatol, 128, 566, 10.1111/j.1365-2133.1993.tb00237.x Langner, 2001, Efficacy and tolerance of topical calcitriol 3mcg/g in psoriasis treatment: a review of our experience in Poland, Br J Dermatol, 144, 11 Lassus, 1980, Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359), Br J Dermatol, 102, 195, 10.1111/j.1365-2133.1980.tb05692.x Layton, 1989, Hydroxyurea in the management of psoriasis, Br J Dermatol, 121, 647, 10.1111/j.1365-2133.1989.tb08198.x Leavell, 1970, Hydroxyurea—a new treatment for psoriasis, Arch Dermatol, 102, 144, 10.1001/archderm.102.2.144 Lebwohl, 1997, Topical application of calcipotriene and corticosteroids: combination regimens, J Am Acad Dermatol, 37, S55 Lerner, 1971, Congenital psoriasis, Arch Dermatol, 105, 561 LeVine, 1980, Outpatient phototherapy of psoriasis, Arch Dermatol, 116, 552, 10.1001/archderm.116.5.552 Lindelof, 1999, PUVA and cancer risk: the Swedish follow-up study, Br J Dermatol, 141, 108, 10.1046/j.1365-2133.1999.02928.x Lomholt, 1963 Loo, 1968, Clinical pharmacologic observations of 6-mercaptopurine and 6-methylthiopurine ribonucleoside, Clin Pharmacol Ther, 9, 180, 10.1002/cpt196892180 Martin, 2001, A multicentre dose-escalation trial with denileukin difitix (ONTAC,DAB389IL-2) in patients with severe psoriasis, J Am Acad Dermatol, 45, 871, 10.1067/mjd.2001.117852 Matheson, 2001, Subcutaneous injections of MEDI-507, an anti-T cell monoclonal antibody, for the treatment of psoriasis: phase 1 results, J Invest Dermatol, 117, 817 Matthews, 1996, Evidence that a locus for familial psoriasis maps to chromosome 4q, Nat Genet, 14, 231, 10.1038/ng1096-231 Mease, 2000, Etenercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 385, 10.1016/S0140-6736(00)02530-7 Molin, 1997, Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized double-blind, parallel group, multicenter study, Br J Dermatol, 136, 89, 10.1111/j.1365-2133.1997.tb08752.x Morris, 1991, Rapamycin: FK506's fraternal twin or distinct cousin?, Immunol Today, 12, 137, 10.1016/S0167-5699(05)80040-4 Moy, 1985, Isotretinoin versus etretinate therapy in generalized pustular and chronic psoriasis, Arch Dermatol, 121, 1297, 10.1001/archderm.121.10.1297 Mrowietz, 2000, Treatment of severe psoriasis with anti-CD25 monoclonal antibodies, Arch Dermatol, 136, 675, 10.1001/archderm.136.5.675 Mueller, 1979, Cyclosporin A for psoriasis, N Engl J Med, 301, 555, 10.1056/NEJM197909063011015 1996, Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study, Arch Dermatol, 132, 419, 10.1001/archderm.132.4.419 Murphy, 1999, Clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis, Arch Dermatol, 135, 1495, 10.1001/archderm.135.12.1495 Nair, 1997, Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan, Hum Mol Genet, 6, 1349, 10.1093/hmg/6.8.1349 Naldi, 1992, Family history, smoking habits, alcohol consumption and risk of psoriasis, Br J Dermatol, 127, 212, 10.1111/j.1365-2133.1992.tb00116.x Nickoloff, 1999, Response of murine and normal human skin to injections of allogeneic blood-derived psoriatic immunocytes, Arch Dermatol, 135, 546, 10.1001/archderm.135.5.546 Niebor, 1990, Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester, Dermatologica, 181, 33, 10.1159/000247856 Nugteren-Huying, 1990, Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study, J Am Acad Dermatol, 22, 311, 10.1016/S0190-9622(08)80766-9 Obuch, 1992, Psoriasis and human immunodeficiency virus infection, J Am Acad Dermatol, 128, 667, 10.1016/0190-9622(92)70234-7 Ockenfels, 1998, The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network, Br J Dermatol, 139, 390, 10.1046/j.1365-2133.1998.02400.x Oh, 2000, Treatment with anti-tumour necrosis factor (TNF-α) a monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions, J Am Acad Dermatol, 42, 829, 10.1067/mjd.2000.105948 Owen, 2000, Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody, Clin Exp Dermatol, 25, 195, 10.1046/j.1365-2230.2000.00612.x Parrish, 1981, Action spectrum for phototherapy of psoriasis, J Invest Dermatol, 76, 359, 10.1111/1523-1747.ep12520022 Phillips, 1987, Pulmonary complications following methotrexate therapy, J Am Acad Dermatol, 16, 373, 10.1016/S0190-9622(87)70052-8 Pilkington, 1992, Acitretin: a review of its pharmacology and therapeutic use, Drugs, 43, 597, 10.2165/00003495-199243040-00010 Reitamo, 2001, Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial, Br J Dermatol, 145, 438, 10.1046/j.1365-2133.2001.04376.x Remitz, 1999, Tacrolimus ointment improves psoriasis in a microplaque assay, Br J Dermatol, 141, 103, 10.1046/j.1365-2133.1999.02927.x Richards, 1999, Patients with psoriasis and their compliance with medication, J Am Acad Dermatol, 41, 581 Roenigk, 1971, Hepatoxicity of methotrexate in the treatment of psoriasis, Arch Dermatol, 103, 250, 10.1001/archderm.103.3.250 Roenigk, 1998, Methotrexate in psoriasis: consensus conference, J Am Acad Dermatol, 38, 478, 10.1016/S0190-9622(98)70508-0 Ros, 1987, Photosensitive psoriasis. An epidemiologic study, J Am Acad Dermatol, 17, 752, 10.1016/S0190-9622(87)70258-8 Salim, 2000, Successful treatment of severe generalised pustular psoriasis with basiliximab (interleukin-2 receptor blocker), Br J Dermatol, 143, 1121, 10.1046/j.1365-2133.2000.03878.x Schalla, 1981, Skin permeability of anthralin, Br J Dermatol, 105, 104, 10.1111/j.1365-2133.1981.tb01022.x Seville, 1976, Relapse rate of psoriasis worsened by adding steroids to a dithranol regimen, Br J Dermatol, 95, 643, 10.1111/j.1365-2133.1976.tb07038.x Seville, 1989, Stress and psoriasis: the importance of insight and empathy in prognosis, J Am Acad Dermatol, 20, 97, 10.1016/S0190-9622(89)70015-3 Singri, 2002, Biological therapy for psoriasis. The new therapeutic frontier, Arch Dermatol, 134, 657, 10.1001/archderm.138.5.657 Speight, 1994, Erythemal and therapeutic response of psoriasis to PUVA using high-dose UVA, Br J Dermatol, 131, 667, 10.1111/j.1365-2133.1994.tb04980.x Spuls, 1998, The development of practice guidelines for the treatment of severe plaque form psoriasis, Arch Dermatol, 134, 1591, 10.1001/archderm.134.12.1591 Stern, 1986, Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomised study, J Am Acad Dermatol, 15, 546, 10.1016/S0190-9622(86)70206-5 Stern, 1997, Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA), N Engl J Med, 336, 1041, 10.1056/NEJM199704103361501 Swanbeck, 1995, Age at onset and different types of psoriasis, Br J Dermatol, 133, 768, 10.1111/j.1365-2133.1995.tb02753.x Szmurlo, 1992, Antitumour action of retinoids: inhibition of tumour cell line-induced angiogenesis and prevention of tumours in mice, Dermatology, 184, 116, 10.1159/000247516 Telfer, 1992, The role of streptococcal infection in the initiation of guttate psoriasis, Arch Dermatol, 128, 39, 10.1001/archderm.128.1.39 Thio, 1994, Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes, Br J Dermatol, 131, 856, 10.1111/j.1365-2133.1994.tb08589.x Tomfohrde, 1994, Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q, Science, 264, 1141, 10.1126/science.8178173 Trehan, 2002, High-dose 308-nm excimer laser for the treatment of psoriasis, J Am Acad Dermatol, 46, 732, 10.1067/mjd.2002.120538 Trembath, 1997, Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis, Hum Mol Genet, 6, 813, 10.1093/hmg/6.5.813 Trepicchio, 1999, Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions, J Clin Invest, 104, 1527, 10.1172/JCI6910 Van de Kerkhof, 1996, Tacalcitol in the treatment of psoriasis vulgaris: a multicenter, placebo-controlled, double-blind study on efficacy and safety, Br J Dermatol, 135, 758, 10.1046/j.1365-2133.1996.d01-1075.x Van Dooren-Greebe, 1994, Methotrexate revisited: effects of long-term treatment in psoriasis, Br J Dermatol, 130, 204, 10.1111/j.1365-2133.1994.tb02901.x Van Scott, 1963, Kinetics of hyperplasia in psoriasis, Arch Dermatol, 88, 373, 10.1001/archderm.1963.01590220005001 Van Wauwe, 1992, Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo, J Pharmacol Exp Ther, 261, 773 Veal, 2001, Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci, J Med Genet, 38, 7, 10.1136/jmg.38.1.7 Veal, 2002, Family based analysis using a dense SNP based map defines genetic variation at PSORS1, the major psoriasis susceptibility locus, Am J Hum Genet, 71, 554, 10.1086/342289 Verbov, 1976, Skin diseases in the old testament, Practioner, 216, 229 Walter, 1978, Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin, Br J Dermatol, 99, 89, 10.1111/j.1365-2133.1978.tb01965.x Weinstein, 1993, An approach to the treatment of moderate to severe psoriasis with rotational therapy, J Am Acad Dermatol, 28, 454, 10.1016/0190-9622(93)70067-4 Weinstein, 1997, Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect, J Am Acad Dermatol, 37, 85, 10.1016/S0190-9622(97)70216-0 Williams, 1992, Re-examining crude coal tar treatment for psoriasis, Br J Dermatol, 126, 608, 10.1111/j.1365-2133.1992.tb00108.x Yamamoto, 2000, Topical tacrolimus is effective for facial lesions in psoriasis, Acta Derm-Venereol, 80, 451 Yarbro, 1969, Hydroxyurea in the treatment of refractory psoriasis, Lancet, 2, 846, 10.1016/S0140-6736(69)92297-1 Zackheim, 1994, 6-Thioguanine treatment of psoriasis: experience in 81 patients, J Am Acad Dermatol, 30, 452, 10.1016/S0190-9622(94)70055-9